Ser699

Site Information
GQLIDLssPLIQLsP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 7322900

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	cervical cancer ( 3 ) , cervical adenocarcinoma ( 3 )
Relevant cell line - cell type - tissue:	HeLa (cervical) ( 1 , 4 ) , HeLa S3 (cervical) ( 3 ) , Jurkat (T lymphocyte) ( 2 )

Upstream Regulation
Treatments:	nocodazole ( 3 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Possemato A (2010) CST Curation Set: 10722; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
3	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
4	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info